Third Line	LEN-DEX	BOR-DEX	CFZ-LEN-DEX	ELO-LEN-DEX	IX- LEN-DEX	PAN-BOR-DEX	DAR-LEN-DEX	DAR-BOR-DEX
Total costs, $	281,754	175,315	459,868	608,651	566,512	190,876	789,202	423,119
Drug acquisition	237,670	121,751	401,201	541,632	516,793	131,500	707,051	344,684
Supportive care	473	1,441	1,779	2,364	2,255	411	4,579	2,403
Administration		7,365	8,113	13,394	–	3,095	22,394	21,412
Progression	39,261	40,175	44,318	44,105	43,298	46,744	51,708	52,014
Adverse event	4,351	4,583	4,457	7,156	4,I66	9,127	3,469	2,607
Total QALYs	2.04	2.16	2.74	2.71	2.60	3.23	4.38	4.38
PFS	1.00	1.07	1.37	1.36	1.30	1.69	2.28	2.35
Progression	1.03	1.09	1.37	1.36	1.30	1.54	2.10	2.03
Total life-years (OS)	3.25	3.44	4.37	4.32	4.14	4.93	6.97	6.71
PFS	1.55	1.64	2.12	2.09	2.00	2.41	3.52	3.38
Progression	1.70	1.79	2.25	2.23	2.14	2.52	3.44	3.33
ICER vs. LEN-DEX	–	-853,800	252,293	484,168	508,021	Dominant	216,360	60,359